- Home
- CANF vs AWH Comparison
CANF vs AWH Comparison
Compare CANF & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- AWH
- Stock Information
- Founded
- CANF 1994
- AWH 1993
- Country
- CANF Israel
- AWH United States
- Employees
- CANF N/A
- AWH N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- AWH Medical/Dental Instruments
- Sector
- CANF Health Care
- AWH Health Care
- Exchange
- CANF Nasdaq
- AWH Nasdaq
- Market Cap
- CANF 14.4M
- AWH 13.5M
- IPO Year
- CANF N/A
- AWH N/A
- Fundamental
- Price
- CANF $2.46
- AWH $0.76
- Analyst Decision
- CANF Strong Buy
- AWH Buy
- Analyst Count
- CANF 2
- AWH 2
- Target Price
- CANF $14.00
- AWH $4.40
- AVG Volume (30 Days)
- CANF 137.2K
- AWH 61.9K
- Earning Date
- CANF 11-15-2024
- AWH 11-11-2024
- Dividend Yield
- CANF N/A
- AWH N/A
- EPS Growth
- CANF N/A
- AWH N/A
- EPS
- CANF N/A
- AWH N/A
- Revenue
- CANF $667,000.00
- AWH $8,923,000.00
- Revenue This Year
- CANF $356.93
- AWH $15.59
- Revenue Next Year
- CANF N/A
- AWH $108.47
- P/E Ratio
- CANF N/A
- AWH N/A
- Revenue Growth
- CANF N/A
- AWH N/A
- 52 Week Low
- CANF $1.81
- AWH $0.74
- 52 Week High
- CANF $4.69
- AWH $6.01
- Technical
- Relative Strength Index (RSI)
- CANF 62.91
- AWH 36.80
- Support Level
- CANF $1.87
- AWH $0.76
- Resistance Level
- CANF $2.55
- AWH $0.89
- Average True Range (ATR)
- CANF 0.17
- AWH 0.06
- MACD
- CANF 0.06
- AWH 0.01
- Stochastic Oscillator
- CANF 85.94
- AWH 18.40
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.